Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Stille AB (STIL.ST)
Torshälla, SE
Stille AB develops, manufactures, and distributes medtech products in Sweden and internationally. It operates through the Surgical Instruments and Surgical Tables segments. The Surgical Instruments segment offers surgical scissors, including SuperCut, eye, blepharoplasty, operating, vascular, tenotomy, and face-lift scissors; colon, gall duct, multi-purpose, tangential occlusion, peripheral vascular, and anastomosis clamps; skin and nerve hooks, retractors, rib spreaders, self-retaining and trachea retractors, and nasal specula; and dressing, diathermy, knot-holding, tissue, iris, dura, and vascular forceps under the STILLE, Fehling, and S&T brands. Its Surgical Tables segment provides C-arm tables, which are surgical tables used in ERCP/abdominal fluoroscopy, neuro/spine, pain management, urology, and vascular procedures under the imagiQ and MedStone brands. The company also offers instrument care education, repair and maintenance, and inspection services. Stille AB was founded in 1841 and is headquartered in Torshälla, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-04 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%-0.4% Q1'26: +38.5% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-4.0% Q1'26: +42.9% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-0.2% Q1'26: +12.5% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+12.8% ★ Q1'26: +17.2% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+7.5% ★ Q1'26: +16.4% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×1.70× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
Dec 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
83.48M
est: 82.40M (+1.3%)
|
96.33M
est: 86.50M (+11.4%)
|
135.80M
est: 82.40M (+64.8%)
|
156.67M
est: 86.50M (+81.1%)
|
187.09M
est: 163.00M (+14.8%)
|
246.35M
est: 254.00M (-3.0%)
|
294.89M
est: 429.68M (-31.4%)
|
569.95M
est: 557.37M (+2.3%)
|
567.63M
est: 408.12M (+39.1%)
|
656.40M
641.80M – 671.00M
+60.8% YoY
|
724.90M
704.50M – 745.30M
+10.4% YoY
|
798.25M
798.25M – 798.25M
+10.1% YoY
|
914.00M
890.84M – 937.16M
+14.5% YoY
|
1.01B
985.38M – 1.04B
+10.6% YoY
|
| EBITDA |
13.94M
est: 13.92M (+0.1%)
|
20.14M
est: 14.62M (+37.8%)
|
27.36M
est: 13.92M (+96.5%)
|
33.26M
est: 14.62M (+127.5%)
|
28.89M
est: 27.54M (+4.9%)
|
44.79M
est: 42.92M (+4.3%)
|
56.04M
est: 74.17M (-24.4%)
|
118.97M
est: 96.21M (+23.7%)
|
72.70M
est: 70.45M (+3.2%)
|
113.30M
110.78M – 115.82M
+60.8% YoY
|
125.13M
121.61M – 128.65M
+10.4% YoY
|
137.79M
137.79M – 137.79M
+10.1% YoY
|
157.77M
153.77M – 161.77M
+14.5% YoY
|
174.51M
170.09M – 178.94M
+10.6% YoY
|
| EBIT |
10.20M
est: 10.41M (-2.1%)
|
16.27M
est: 10.93M (+48.8%)
|
25.62M
est: 10.41M (+146.1%)
|
29.47M
est: 10.93M (+169.6%)
|
22.14M
est: 20.60M (+7.5%)
|
35.14M
est: 32.10M (+9.5%)
|
41.68M
est: 58.36M (-28.6%)
|
84.74M
est: 75.70M (+11.9%)
|
72.70M
est: 55.43M (+31.1%)
|
89.15M
87.17M – 91.13M
+60.8% YoY
|
98.45M
95.68M – 101.22M
+10.4% YoY
|
108.42M
108.42M – 108.42M
+10.1% YoY
|
124.14M
120.99M – 127.28M
+14.5% YoY
|
137.31M
133.83M – 140.79M
+10.6% YoY
|
| Net Income |
10.50M
est: 7.19M (+46.0%)
|
16.79M
est: 7.82M (+114.8%)
|
20.18M
est: 7.19M (+180.7%)
|
22.88M
est: 7.82M (+192.7%)
|
16.10M
est: 33.25M (-51.6%)
|
27.32M
est: 55.71M (-51.0%)
|
26.65M
est: 61.43M (-56.6%)
|
58.21M
est: 77.25M (-24.7%)
|
55.70M
est: 45.19M (+23.3%)
|
78.15M
75.58M – 80.72M
+72.9% YoY
|
95.98M
92.82M – 99.14M
+22.8% YoY
|
110.88M
107.23M – 114.53M
+15.5% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
29.29M
est: 25.88M (+13.2%)
|
29.96M
est: 27.17M (+10.3%)
|
35.74M
est: 25.88M (+38.1%)
|
39.53M
est: 27.17M (+45.5%)
|
60.15M
est: 51.20M (+17.5%)
|
80.07M
est: 79.78M (+0.4%)
|
84.48M
est: 139.36M (-39.4%)
|
183.47M
est: 180.77M (+1.5%)
|
208.18M
est: 132.37M (+57.3%)
|
212.89M
208.16M – 217.63M
+60.8% YoY
|
235.11M
228.49M – 241.72M
+10.4% YoY
|
258.90M
258.90M – 258.90M
+10.1% YoY
|
296.44M
288.93M – 303.95M
+14.5% YoY
|
327.90M
319.59M – 336.21M
+10.6% YoY
|
| EPS |
2.17
est: 0.80 (+171.3%)
|
3.48
est: 0.87 (+300.0%)
|
4.26
est: 0.80 (+432.5%)
|
4.74
est: 0.87 (+444.8%)
|
3.21
est: 3.70 (-13.2%)
|
5.45
est: 6.20 (-12.1%)
|
5.31
est: 6.84 (-22.3%)
|
6.46
est: 8.60 (-24.9%)
|
6.20
est: 5.03 (+23.3%)
|
8.70
8.41 – 8.98
+72.9% YoY
|
10.68
10.33 – 11.03
+22.8% YoY
|
12.34
11.93 – 12.75
+15.5% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Brian Anderson | Chief Executive Officer of Stille Surgical, Inc. | — | male |
| Gerald Fehling | Chief Executive Officer of Fehling Instruments | — | male |
| John Anderson | Head of Development | — | — |
| Markus Spingler | Chief Executive Officer of S&T | — | male |
| Niklas Tyren | Group CFO & Member of Management Board | — | male |
| Per Killiner | Interim Chief Financial Officer | — | male |
| Ulrik Berthelsen | President, Chief Executive Officer & Member of Management Board | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for STIL.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
